Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuankai Shi

Showing results (301-310 of 347) with videos related to

Pageof 35
Sort By:
The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Translational Lung Cancer Research|June 13, 2022
The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 studyYizhuo Zhao, Qiming Wang, Li Zhang, et al.
The Lancet Regional Health. Western Pacific|July 12, 2024
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic <i>EGFR</i> mutation-positive non-small cell lung cancerYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Cancer Immunology, Immunotherapy : CII|November 24, 2021
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapyQiaoyun Tan, Liyuan Dai, Yanrong Wang, et al.
The Lancet. Respiratory Medicine|July 19, 2018
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trialZhijie Wang, Ying Cheng, Tongtong An, et al.
Translational Lung Cancer Research|November 19, 2019
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trialLili Wang, Zhen He, Sen Yang, et al.
ESMO Open|December 7, 2017
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancerFiona Blackhall, D Ross Camidge, Alice T Shaw, et al.
Journal of Cancer Research and Clinical Oncology|February 21, 2019
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progressionMartin Schuler, Eng-Huat Tan, Kenneth O'Byrne, et al.
Journal of Hematology & Oncology|February 16, 2021
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 studyHuiqiang Huang, Jun Zhu, Ming Yao, et al.
Pageof 35

Showing results (301-310 of 347) with videos related to

Sort By:
Pageof 35
The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Translational Lung Cancer Research|June 13, 2022
The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 studyYizhuo Zhao, Qiming Wang, Li Zhang, et al.
The Lancet Regional Health. Western Pacific|July 12, 2024
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic <i>EGFR</i> mutation-positive non-small cell lung cancerYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Cancer Immunology, Immunotherapy : CII|November 24, 2021
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapyQiaoyun Tan, Liyuan Dai, Yanrong Wang, et al.
The Lancet. Respiratory Medicine|July 19, 2018
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trialZhijie Wang, Ying Cheng, Tongtong An, et al.
Translational Lung Cancer Research|November 19, 2019
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trialLili Wang, Zhen He, Sen Yang, et al.
ESMO Open|December 7, 2017
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancerFiona Blackhall, D Ross Camidge, Alice T Shaw, et al.
Journal of Cancer Research and Clinical Oncology|February 21, 2019
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progressionMartin Schuler, Eng-Huat Tan, Kenneth O'Byrne, et al.
Journal of Hematology & Oncology|February 16, 2021
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 studyHuiqiang Huang, Jun Zhu, Ming Yao, et al.
Pageof 35